Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes

Abstract Background and aims Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2017-09, Vol.264, p.108-114
Main Authors: Samman Tahhan, Ayman, Hayek, Salim, Sandesara, Pratik, Hajjari, Jamal, Hammadah, Muhammad, O'Neal, Wesley T, Kelli, Heval M, Alkhoder, Ayman, Ghasemzadeh, Nima, Ko, Yi-An, Aida, Hiroshi, Gafeer, Mohamad Mazen, Abdelhadi, Naser, Hosny, Kareem, Patel, Keyur, Arya, Shipra, Reiser, Jochen, Vaccarino, Viola, Sperling, Laurence, Quyyumi, Arshed
Format: Article
Language:English
Subjects:
Aged
Atherosclerosis
Biomarkers - blood
CAD
Cardiovascular
Cardiovascular outcomes
Case-Control Studies
Chi-Square Distribution
Coronary Artery Disease - blood
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - epidemiology
Coronary Artery Disease - mortality
Female
Georgia - epidemiology
Humans
Incidence
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Multivariate Analysis
Odds Ratio
PAD
PAD-Related outcomes
Peripheral Arterial Disease - blood
Peripheral Arterial Disease - diagnostic imaging
Peripheral Arterial Disease - epidemiology
Peripheral Arterial Disease - mortality
Prevalence
Prognosis
Proportional Hazards Models
Receptors, Urokinase Plasminogen Activator - blood
Risk Factors
SuPAR
Time Factors
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and aims Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study. Methods SuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD. Results Plasma suPAR levels were 22.5% ( p  
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2017.06.019